| Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat SH Park, MA Farooq, S Gaertner, C Bruckert, AW Qureshi, HH Lee, ... Cardiovascular diabetology 19, 1-14, 2020 | 90 | 2020 |
| Development of carbon monoxide-releasing molecules conjugated to polysaccharides (glyco-CORMs) for delivering CO during obesity S Mohan, LA Barel, DE Benrahla, B Do, Q Mao, H Kitagishi, M Rivard, ... Pharmacological Research 191, 106770, 2023 | 4 | 2023 |
| CORM-401, an orally active carbon monoxide-releasing molecule, increases body temperature by activating non-shivering thermogenesis in rats MR Amorim, R Foresti, DE Benrahla, R Motterlini, LGS Branco Temperature 9 (4), 310-317, 2022 | 2 | 2022 |
| Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, improved heart remodelling and endothelial and vascular dysfunction in ZSF1 rats with metabolic syndrome C Bruckert, SH Park, MA Farooq, S Gaertner, AW Qureshi, HH Lee, ... Diabetologia 62, S539-S539, 2019 | 2 | 2019 |
| An orally active carbon monoxide-releasing molecule enhances beneficial gut microbial species to combat obesity in mice DE Benrahla, S Mohan, M Trickovic, FA Castelli, G Alloul, A Sobngwi, ... Redox Biology 72, 103153, 2024 | | 2024 |
| Metal‐Based Carbon Monoxide‐Releasing Molecules (CO‐RMs) as Pharmacologically Active Therapeutics R Foresti, DE Benrahla, S Mohan, R Motterlini Carbon Monoxide in Drug Discovery: Basics, Pharmacology, and Therapeutic …, 2022 | | 2022 |
| Empagliflozin, a sodium-glucose cotransporter inhibitor, improved heart remodeling and mesenteric artery endothelial function in the metabolic syndrome with HFpEF ZSF1 rat … SH Park, MA Farooq, S Gaertner, C Bruckert, A Qureshi, H Lee, ... Archives of Cardiovascular Diseases Supplements 11 (2), 227-228, 2019 | | 2019 |
